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Abstract
Background—Retention of children in HIV care is essential for prevention of disease 
progression and mortality.
Methods—Retrospective cohort of children (0 to <15 years) initiating antiretroviral treatment 
(ART) at health facilities in Kenya, Mozambique, Rwanda and Tanzania, January 2005–June 2011. 
Retention was defined as the proportion of children known to be alive and attending care at their 
initiation facility; lost to follow-up (LTF) was defined as no clinic visit for > 6 months. Cumulative 
incidence of ascertained survival and retention after ART initiation was estimated through 24 
months using Kaplan-Meier methods. Factors associated with LTF and death were assessed using 
Cox proportional hazard modeling.
Results—17,712 children initiated ART at 192 facilities: median age was 4.6 years (IQR: 1.9–
8.3), median CD4 was 15% (IQR: 10–20) for children < 5 years and 265 cells/uL (IQR: 111–461) 
for children ≥ 5 years. At 12 and 24 months, 80% and 72% of children were retained with 16% 
and 22% LTF and 5% and 7% known deaths respectively. Retention ranged from 71–95% and 62–
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93% at 12 and 24 months across countries, and was lowest for children < 1 year (51% at 24 
months). LTF and death were highest in children < 1 year of age and children with advanced 
disease.
Conclusion—Retention was lowest in young children and differed across country programs. 
Young children and those with advanced disease are at highest risk for LTF and death. Further 
evaluation of patient- and program-level factors is needed to improve health outcomes.
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INTRODUCTION
Scale up of pediatric HIV care and treatment across sub-Saharan Africa (SSA), where over 
90% of children living with HIV reside1, has been substantial with more than 387,000 
children reported as initiating antiretroviral therapy (ART) by December 20102. Treatment 
responses of children on ART in resource-limited settings have been robust3–9 with high 
rates of viral suppression and immune reconstitution as well as improved survival10–15. 
However, the mortality rate of children on ART in resource-limited settings is considerably 
higher than the rate in developed countries, 8.0 versus 0.9 deaths per 100 child-years (p < 
0.001) respectively16. Reasons for this disparity include both biomedical and programmatic 
factors such as advanced disease at time of presentation, fragility of infants and younger 
children, other infectious co-morbidities and malnutrition, delays in ART initiation, and 
suboptimal retention in care4,13.
Retention of HIV-infected children in care is essential for prevention of HIV-related 
morbidity and mortality through timely ART initiation, monitoring and management of 
disease progression and treatment failure, and provision of medications and supportive care. 
Pediatric programs in SSA report retention ranging from 77–89% at 12 and 24 
months11,14,15,17–19 which may jeopardize long-term health outcomes20. Both patient and 
programmatic factors influencing retention need to be identified to improve outcomes and 
inform future interventions.
We examined retention, lost to follow-up (LTF) and death among 17,712 children, less than 
15 years of age, initiating ART at 192 health facilities in Kenya, Mozambique, Rwanda, and 
Tanzania from January 2005 through June 2011. The objectives of this analysis were to 
determine the proportion of children who were retained, LTF and died at 12 and 24 months, 
to assess variation in retention outcomes by country, and to identify patient- and facility-
level factors associated with these outcomes.
METHODS
Study Population
We conducted a retrospective cohort analysis of all children, < 15 years of age, initiating 
ART at 192 HIV care facilities in Kenya, Mozambique, Rwanda and Tanzania from January 
2005–June 2011. All facilities received support from ICAP, a President’s Emergency Plan 
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for AIDS Relief (PEPFAR) implementing partner that has been supporting HIV care and 
treatment in SSA since 2005. ICAP is a nongovernmental organization at the Mailman 
School of Public Health at Columbia University that supports scale-up of HIV care and 
treatment through facility mentorship of facility staff, renovation of laboratory and health 
facilities, creation and support of monitoring and evaluation tools and practices, and other 
technical assistance21. All health facilities included in this analysis participate in the 
Identifying Optimal Models of HIV Care and Treatment Study (5U2GPS001537-03)22 
which uses routinely collected patient- and facility-level data to measure patient and 
program outcomes. All facilities had electronic patient-level databases, which are password 
protected, and encrypted de-identified databases are transferred to ICAP offices every 
quarter where they are aggregated for analysis. Clinical and laboratory data was recorded by 
facility staff onto paper records and clerks then data was transferred from paper records into 
an electronic patient database; data quality assessments were done every 6 months to assess 
for completeness and accuracy of data entry.
Eligibility criteria for ART initiation followed each country’s national guidelines which 
reflect WHO recommendations23,24. Per WHO 2006 guidelines, children < 5 years were 
eligible for ART if they had WHO Stage III/IV, CD4 percentage < 25% (<12 months), CD4 
percentage <20 % (12–35 months) or CD4 percentage < 15% (36–59 months). For children 
> 5 years old, ART eligibility included 1) WHO Stage IV, 2) WHO stage III and CD4 < 350 
cells/uL, or 3) CD4< 200 cells/uL irrespective of WHO Stage23. From 2006 to 2011, all four 
countries began adopting revised WHO guidelines, including recommendations for ART for 
all HIV-infected children < 1 year25–28, later updated to < 2 years regardless of CD4 
measurement24,29,30. Standard of care for HIV care and ART regimens followed national 
guidelines, which recommended ART for eligible children beginning in 200623. 
Recommended facility follow-up was a minimum of every 3 months with semi-annual CD4 
testing. Access to CD4 testing was not always available but improved over time with 
increased access to CD4 analyzers and decentralization of laboratories.
Definitions and Outcomes
Follow-up time on ART was estimated as the time between date of ART initiation and either 
documented transfer, death, LTF, or completion of the observation period. Children were 
considered retained if they were known to be alive and continuing ART at their initiation 
facility. Mortality was passively ascertained from documentation of death in patient records. 
LTF was defined as having no recorded visit for 6 months with no visits after the last missed 
visit, as per by Chi et al31, and non-retention was defined as either death or LTF. Children 
who were LTF were censored 15 days after their last recorded visit. Children documented to 
have transferred to another facility were censored at their recorded date of transfer.
Individual-level factors were chosen based on available data across all country datasets and 
factors known or suspected through previous research to influence retention and survival. 
The CD4 percent or cell count and WHO stage taken closest to the date of ART initiation, 
within a window of 3 months prior to or up to one month after ART initiation, was used to 
determine disease severity at ART initiation. Clinical stage and immunologic category were 
defined according to 2006 WHO guidelines: severe immunodeficiency is defined as CD4 < 
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25% or < 1500 cells/uL in children ≤ 11 months, CD4 < 20% or < 750 cells/uL in children 
age 12 to 35 months, CD4 < 15% or < 350 cells/uL in children age 36 to 59 months and 
CD4 < 15% or < 200 cells/uL in children > 5 years23. To investigate the potential influence 
of malnourishment in our population, we constructed weight-for-age z- scores and 
categorized children as z-score ≤ or > −2 standard deviations32. No reliable data was 
available for TB status or treatment at the time of ART initiation. A new category of “severe 
illness” was created to include any child with severe immunodeficiency, defined above, or 
WHO Stage IV at time of ART initiation because of the high proportion of missing CD4 
measurements and WHO stage.
Facilities were defined as primary or secondary/tertiary. A primary facility is any health 
center; secondary and tertiary facilities are district, regional, or national hospitals. Facility 
location was categorized into urban (capital and other large cities with city administration 
and political bodies), semi-urban (big and small towns, peri-urban areas, growth areas, and 
mining communities), and rural (small towns, and farming areas).
Statistical Analysis
Cumulative incidence of non-retention, LTF, and reported death through 24 months after 
ART initiation were estimated using Kaplan-Meier techniques. In the primary analysis, Cox 
Proportional Hazards models accounting for within-clinic correlation between patients with 
robust sandwich error terms were used to assess the association between measured patient 
and facility-level characteristics and LTF and documented death after ART initiation. 
Individual-level factors include age, point of entry, weight-for-age z-score at ART initiation, 
CD4 measure at ART initiation, WHO stage at ART initiation, and year of ART initiation; 
facility-level factors include country, facility type and setting.
Ethical Considerations
This study is part of the Identifying Optimal Models of HIV Care and Treatment, which was 
approved by the Columbia University Medical Center IRB, the US Centers for Disease 
Control and Prevention, PEPFAR’s Office of the Global AIDS Coordinator (OGAC), and 
each participating country’s national ethics committee.
RESULTS
Characteristics of HIV Care Programs
From January 2005 through June 2011, 37,154 children were enrolled in HIV services at 
192 facilities in Kenya, Rwanda, Tanzania, and Mozambique (Table 1). A total of 17,712 
children initiated ART with the largest cohort in Mozambique (7,226) and the smallest in 
Rwanda (2,170). The number of children initiated on ART increased annually from 585 in 
2005 to 3,653 in 2010, the last full year of observation, with the number of facilities 
increasing from 75 to 192. Half of the facilities (54%) were in primary-level health centers 
as compared to secondary (district/regional hospitals) or tertiary-level facilities (teaching or 
national referral hospitals). Half of facilities (49%) were in rural locations (Table 1) and the 
majority of facilities were government-supported.
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Median follow-up time for children initiated on ART was 598 days (IQR: 245–1,106). The 
median age at ART initiation was 4.6 years (IQR: 1.9–8.3) with a similar distribution of 
females (51%) and males. Forty-eight percent of children had WHO Stage III/IV disease, 
and 32% of children had severe immunodeficiency (67% of children < 5 years and 38% of 
children ≥ 5 years). Thirty-three percent of children had a weight-for-age z-score of ≤ −2. 
Among the 8,263 children with recorded CD4 measurements (33% for children < 5 years 
and 62% of children ≥ 5 years) at ART initiation, the median CD4 was 15% (IQR: 10–20) 
for children < 5 years and 265 cells/uL (IQR:111–461) for children ≥ 5 years (Table 1). 
Overall, 34.5% of children were classified with severe illness at time of ART initiation 
(Table 1) and the proportion of children < 1 year classified with severe illness decreased 
from 56% in 2006 to 18% in 2011 (Supplemental Table 1). Over time, the proportion of 
children < 2 years of age initiated on ART increased from 12% of all children in 2005 to 
33% in 2011 (Figure 1). The majority of all children reported entry into HIV care through 
voluntary counseling and testing or provider initiated counseling and testing (Table 1). First-
line ART regimens for 95% of children included two nucleoside reverse transcriptase 
inhibitors plus one non-nucleoside reverse transcriptase inhibitor.
Country programs varied in the proportion of young (< 2 years) and severely ill children. 
Rwanda reported the smallest proportion of young children, 15.6% as compared to 38.7% in 
Mozambique. Rwanda also reported the smallest proportion of children with severe illness at 
18.6% compared to 44.5% in Mozambique, 36.5% in Tanzania, and 26.9% in Kenya. 
Tanzania had the largest proportion of children with documented WHO Stage IV, 26.2%, as 
compared to Kenya (4.5%); however over 30% of children in Mozambique did not have 
WHO stage recorded.
Retention, LTF and Mortality at 12 and 24 months
Among those initiated on ART, 80% and 72% of children were retained at 12 and 24 months 
(Table 2, Figure 2a). At 12 and 24 months, 16% and 22% of children were LTF, while 5% 
and 7% had documented deaths (Table 2). LTF and mortality rates were highest in the first 6 
months after ART initiation (26.3 and 9.1 per 100 person-years, respectively), declining 
through 12 months (18.4 and 6.3 per 100 person-years) and 24 months (14.2 and 4.5 per 100 
person-years). Retention varied substantially across countries, ranging from 71–95% at 12 
months and 62–93% at 24 months (Table 2, Figure 2b). Compared to children in Rwanda, 
children in Mozambique had 16 fold higher rate of LTF (adjusted HR 16.8, 95% CI 8.9–
32.0) and children in Tanzania had over two times higher death rate (adjusted HR 2.6, 95% 
CI 1.8–3.6). All country programs experienced the largest drop in retention during the first 
six months after ART initiation. Across all age groups and time periods, the proportion of 
children who were LTF was higher than the proportion of known deaths, except for Rwanda. 
The overall proportion of documented transfers was similar across programs: 18% Kenya, 
12% Mozambique, 19% Rwanda, and 15% Tanzania.
Retention was lowest among children < 1 year, 61% and 51% at 12 and 24 months, and 
highest in children age 5 to < 10 years, 87% and 80% respectively (Table 2, Figure 2c). 
There was no consistent improvement in retention, LTF or death in children < 1 year over 
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time by calendar year although LTF appeared to be marginally lower in later years 
(Supplemental Table 2).
Factors associated with LTF and death
Multivariable analysis was done to assess factors associated with LTF and death including 
country, age at ART initiation, severe illness at ART initiation, weight-for-age z-score at 
ART initiation, year of ART initiation, point of entry into HIV care, and facility type and 
location. The adjusted hazard ratio for LTF and death were highest in children < 1 year 
(HRLTF =2.0, 95% CI 1.7–2.4; HRDeath= 3.4, 95% CI: 2.6–4.6) (Table 3). Compared to 
children with less advanced disease, children with severe illness had higher rate of death 
(HRDeath =1.6, 95% 1.4–1.9) but similar rate of LTF (HRLTF = 0.99, 95% CI 0.86–1.13) 
(Table 3). Among older children, CD4 count was a strong predictor of LTF and death; 
children ≥ 5 years with CD4 < 100 cells/uL had nearly three times higher death rates 
compared with children initiating ART at CD4 > 350 cells/uL. Children with missing CD4 
counts had 2.3 times the rate of death compared to children with a CD4 > 350 cells/uL; and 
children missing WHO stage or severe illness information were also more likely than other 
children to be LTF or to be documented deaths. There was no evidence of differences in 
LTF, or death by point of entry or facility type (Table 3). There was no consistent evidence 
for reduced LTF, or death by year of ART initiation. No facility-level factors were found to 
have a significant impact on the risk of LTF or death.
Results were also stratified by country (Supplemental Table 3) and similar factors are 
associated with increased risk of LTF and death across all countries. Sensitivity analyses 
using random effects multilevel Cox Proportional Hazards models, in addition to the fixed 
effects model presented, yielded no substantial differences in the magnitude of the hazard 
ratios presented in Table 3.
DISCUSSION
To our knowledge, this is the largest reported cohort of children on ART across multiple 
African countries, which reflects the scale-up of HIV care and treatment across Sub Saharan 
Africa. At 12 and 24 months, 80% and 72% of children were retained in care, 16% and 22% 
were LTF and 5% and 7% were known to have died. The true proportion of children who 
have died is likely much higher than reported values given some children who are 
categorized as LTF are undocumented deaths18,33. While this study’s outcomes are similar 
to other cohorts7,11,14,15,17–19,22,34,35, there was substantial variation within specific 
populations of children, particularly the youngest (< 1 year) and those with advanced 
disease, and across country programs.
One of the most striking findings of this study is the outcomes seen among the youngest 
children initiating ART (< 1 year of age). While young age, as well as advanced disease, has 
been associated with increased risk of LTF and death4,7,13–15,17,36–39, the fact that only half 
of children who initiated ART during infancy were retained in care at 24 months and 18% 
have died is sobering (Table 2). While these estimates can be considered an improvement 
from the reports in the pre-ART era (50% mortality at 24 months), the mortality rates remain 
unacceptably high in the context of ART40.
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From 2005 through 2011 we observed an increase in the proportion of young children (both 
infants < 1 year and young children 1 to 2 years) initiating ART (Figure 1) and a 
concomitant decrease in the severity of illness among infants (Supplemental Table 1). These 
findings reflect improved access to early diagnostic testing in the four countries41, as well as 
implementation of the WHO guidelines recommending treatment of all children < 1 year of 
age, later revised to < 2 years of age. However, despite a decrease in the proportion of 
infants categorized as severely ill at time of ART initiation from 2005 to 2011, as noted, 
there was no concurrent improvement in retention or mortality over time (Supplemental 
Table 2). We would anticipate improved outcomes with the enrollment of healthier children 
and the accrual of benefits from early treatment5,6,10. While it is encouraging to see greater 
numbers of young children initiating earlier treatment, further research is needed to identify 
other factors impacting health outcomes among this highly vulnerable group of children. 
These findings also underscore the ongoing need for special attention for infants to be 
promptly diagnosed, initiated on treatment and retained in care.
Another striking finding of this study is the fact that country programs contributing to this 
analysis achieved vastly different outcomes, with retention at 24 months ranging from 62–
93%. Moreover, within countries we observed substantial heterogeneity in both retention 
and mortality. All facilities received technical support through ICAP and implemented the 
same general model of care, which emphasizes early infant diagnosis, family-focused care, 
involvement of peer-educators, and active follow-up. However, possible reasons explaining 
such differences in country outcomes likely include a combination of national influences, 
such as national leadership, access to health services and requirements for medical record 
documentation, as well as epidemiological and program factors such as HIV seroprevalence 
(ranging from 2.9% in Rwanda to 11.5% in Mozambique42), patient caseload, provider-
patient ratios, and decentralization of services. Since the proportion of documented transfers 
is fairly similar across programs, variability in quality of documentation of transfers may 
explain some but not all of the variation seen in retention.
The high retention observed in Rwanda is consistent with other studies investigating 
retention in HIV programs in this country43–46. The ICAP-supported program in Rwanda, in 
comparison to the other country programs included in this study, had a smaller proportion of 
young (age < 2 years) and severely ill children at time of ART initiation. Also, the Rwanda 
program is smaller with a lower patient caseload, 2,170 children in Rwanda as compared to 
7,226 children in ICAP-Mozambique (Table 1), that has been associated with lower LTF in 
resource limited settings47,48. Smaller programs may have higher staff to patient ratios, 
shorter wait times, and more staff and time for active patient follow-up, which has been 
shown to significantly decrease LTF49–51. Finally, better documentation may explain some 
of the differences seen among countries. In Rwanda, the proportion of children who are LTF 
is lower than the proportion of known deaths, for which the reverse is true in other country 
programs. The category of LTF serves as a combination category of children who have been 
truly lost to follow-up and others who have undocumented deaths or transfers. Rwanda’s 
results are encouraging as they illustrate what is achievable in public programs and suggest 
that improvement is obtainable. Additional evaluation of program and facility-level factors, 
not available in this dataset, to explain variations seen across countries is clearly warranted.
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There are a number of strengths to this analysis. The first is that it is the largest, single 
program, multi-country analysis reporting outcomes of children on ART over the period of 
PEPFAR scale-up beginning in 2005. The results are likely generalizable to other PEPFAR-
supported pediatric HIV programs and reflect the diversity in outcomes from rapid scale-up 
of ART for children across SSA. The use of patient-level data allows analysis within age 
categories and links patient-level data to facility data. Finally, we were able to assess 
retention, LTF and death across a relatively long follow-up period of 24 months.
An important limitation of this analysis is the amount of missing data for patient 
characteristics at time of ART initiation, which may be due to poor documentation as well as 
lack of clinical staging and limited access to CD4 testing. The large amount of missing data 
prevented the use of imputation techniques. Instead, we chose to include “missing” as a 
separate category in our regression analyses to investigate whether children with missing 
information differed from children with complete information in outcomes of interest, and 
indeed children with missing data appear to be at increased risk for LTF or death. This is not 
surprising as clinicians report that some children entering HIV care programs attend only 
one clinic visit and do not return to complete full enrollment evaluation including CD4 
assessment. Second, this study only includes ICAP-supported pediatric HIV facilities that 
have capacity for electronic patient-level database, which may represent higher-resourced 
facilities as compared to others. A total of 192 facilities were included representing 31% of 
ICAP-supported care and treatment facilities in Kenya (24%), Rwanda (88%), Mozambique 
(47%), and Tanzania (39%) and regional differences within countries were not analyzed. 
Finally, this analysis does not include HIV-exposed infants, HIV-infected children who have 
not enrolled in care, or those who have enrolled in care but have not initiated ART—all 
groups which have lower estimated retention rates12,22,34,52–54.
It is established that the benefits of ART on children in resource-limited settings are 
comparable with those in developed countries3–9; yet, these benefits are not currently 
realized in many pediatric HIV programs, such as those presented in this analysis. This 
study builds upon the evidence that overall retention, LTF and death are suboptimal, and 
young children and those with advanced disease are at highest risk for LTF and death. 
Despite encouraging results suggesting enrollment of a larger proportion of younger children 
and a smaller proportion of those with severe illness, we do not yet see substantial 
improvement in reported retention, LTF or death of young children. The vast differences 
across country programs illustrate that improved retention is achievable. However, additional 
attention to prompt diagnosis, early ART initiation, active follow-up of children who miss 
appointments and improved documentation of known transfers and deaths are urgent 
priorities for pediatric HIV programs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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country (2b) and retention by age group (2c)
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